Quick Answer
Rein Therapeutics, Inc. reported Stockholders Equity of $16.92 million for fiscal year 2025.
Rein Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $16.92M | -68.9% |
| 2024 | $54.39M | -44.7% |
| 2023 | $98.30M | +427.8% |
| 2022 | $18.62M | -57.6% |
| 2021 | $43.90M | +261.0% |
| 2020 | $12.16M | -24.2% |
| 2019 | $16.05M | -18.1% |
| 2018 | $19.60M | -59.0% |
| 2017 | $47.80M | +142.7% |
| 2016 | -$111.81M | -18.5% |
| 2015 | -$94.32M | -15.0% |
| 2014 | -$82.04M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $46.19M | -51.5% | -3.8% |
| June 30, 2025 | $48.01M | -52.5% | -3.7% |
| March 31, 2025 | $49.88M | -45.4% | -8.3% |
| December 31, 2024 | $54.39M | -44.7% | -42.9% |
| September 30, 2024 | $95.23M | +750.4% | -5.7% |
| June 30, 2024 | $101.02M | +689.6% | +10.6% |
| March 31, 2024 | $91.33M | +539.9% | -7.1% |
| December 31, 2023 | $98.30M | +427.8% | +777.8% |
- Rein Therapeutics, Inc. showed a decrease of -68.9% in Stockholders Equity compared to the prior fiscal year.
- Over the 2014–2025 period, Rein Therapeutics, Inc.’s stockholders equity has grown by 120.6% (from -$82.04 million to $16.92 million).
- The most recent figure is from Rein Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: